| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|
Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q4 2024 | 55 | $2.54B | +$22.5M | -$28.9M | -$6.4M | PG, XOM, CMI, ETN, CSCO | 13F-HR | 2/4/2025, 10:37 AM |
| Q3 2024 | 54 | $2.67B | $0 | $0 | PG, XOM, QCOM, KO, TXN | 13F-HR | 10/25/2024, 04:40 PM | |
| Q2 2024 | 54 | $2.46B | $0 | -$1.56M | -$1.56M | QCOM, PG, XOM, CVX, MRK | 13F-HR | 7/29/2024, 10:44 AM |
| Q1 2024 | 54 | $2.54B | $0 | -$322M | -$322M | XOM, PG, MRK, CVX, QCOM | 13F-HR | 4/29/2024, 08:21 AM |
| Q4 2023 | 58 | $2.65B | +$44M | -$196M | -$152M | QCOM, HUBB, CAT, PG, XOM | 13F-HR | 2/6/2024, 06:16 PM |
| Q3 2023 | 59 | $2.68B | +$31.8M | -$307M | -$275M | XOM, CVX, CAT, HUBB, PG | 13F-HR | 11/6/2023, 09:33 AM |
| Q2 2023 | 61 | $3.05B | $0 | -$72.2M | -$72.2M | HUBB, MRK, CAT, XOM, CVX | 13F-HR | 8/4/2023, 09:17 AM |
| Q1 2023 | 61 | $3.13B | +$13.5M | -$97.5M | -$84M | XOM, CVX, MRK, QCOM, CAT | 13F-HR | 5/18/2023, 01:46 PM |
| Q4 2022 | 62 | $3.19B | +$20.9M | -$260M | -$239M | CVX, NUE, XOM, MRK, CAT | 13F-HR | 2/21/2023, 05:18 PM |
| Q3 2022 | 63 | $3.01B | $0 | -$905M | -$905M | XOM, CAT, VZ, PFE, CVX | 13F-HR | 11/17/2022, 06:36 PM |
| Q2 2022 | 79 | $4.15B | +$33.3M | -$523M | -$490M | XOM, KO, VZ, CVX, CAT | 13F-HR | 8/12/2022, 04:19 PM |
| Q1 2022 | 87 | $4.93B | +$17.9M | -$548M | -$530M | CAT, XOM, CVX, KO, VZ | 13F-HR | 5/13/2022, 02:09 PM |
| Q4 2021 | 92 | $5.26B | +$40.7M | -$13.2M | +$27.6M | QCOM, CAT, PG, VZ, PFE | 13F-HR | 2/17/2022, 03:43 PM |
| Q3 2021 | 92 | $4.79B | +$127M | -$310M | -$183M | VZ, CAT, PG, KO, XOM | 13F-HR | 11/4/2021, 10:17 AM |
| Q2 2021 | 92 | $5.16B | +$809M | $0 | +$809M | CAT, VZ, XOM, CVX, KO | 13F-HR | 7/29/2021, 01:50 PM |
| Q1 2021 | 85 | $4.24B | +$38.2M | -$195M | -$157M | CAT, VZ, XOM, CVX, T | 13F-HR | 5/17/2021, 01:00 PM |
| Q4 2020 | 86 | $4.02B | $0 | $0 | VZ, CAT, KO, QCOM, PG | 13F-HR | 3/3/2021, 09:41 AM | |
| Q3 2020 | 86 | $3.65B | +$49.1M | -$6.55M | +$42.6M | VZ, PG, T, KO, CAT | 13F-HR | 11/4/2020, 12:14 PM |
| Q2 2020 | 83 | $3.53B | $0 | -$7.46M | -$7.46M | VZ, T, CVX, XOM, PG | Restatement | 11/4/2020, 11:29 AM |
| Q1 2020 | 84 | $3.19B | +$244M | -$115M | +$129M | VZ, T, KO, PG, XOM | 13F-HR | 5/6/2020, 05:34 PM |
| Q4 2019 | 83 | $4B | +$386M | -$258M | +$127M | T, VZ, XOM, CVX, KO | 13F-HR | 1/29/2020, 11:13 AM |
| Q3 2019 | 86 | $3.74B | +$102M | -$308M | -$206M | T, VZ, KO, CVX, PG | 13F-HR | 10/31/2019, 01:32 PM |
| Q2 2019 | 87 | $3.86B | +$140M | -$36.6M | +$104M | VZ, T, CVX, KO, XOM | 13F-HR | 8/13/2019, 09:53 AM |
| Q1 2019 | 88 | $3.71B | +$220M | -$224M | -$4.57M | VZ, T, CVX, XOM, KO | 13F-HR | 4/26/2019, 11:30 AM |
| Q4 2018 | 93 | $3.35B | +$318M | -$120M | +$198M | VZ, T, CVX, XOM, KO | 13F-HR | 1/28/2019, 07:05 PM |
| Q3 2018 | 93 | $3.44B | +$79M | -$16.1M | +$62.9M | VZ, T, CVX, XOM, BP | 13F-HR | 10/31/2018, 11:00 AM |
| Q2 2018 | 89 | $3.24B | +$295M | -$228M | +$67.1M | VZ, T, CVX, XOM, RDSB | 13F-HR | 8/3/2018, 11:32 AM |
| Q1 2018 | 84 | $3.12B | +$104M | $0 | +$104M | T, VZ, CVX, RDSB, BP | Restatement | 5/18/2018, 12:52 PM |
| Q4 2017 | 82 | $3.15B | +$450M | -$459M | -$9.21M | T, VZ, CVX, RDSB, BP | 13F-HR | 2/20/2018, 10:19 AM |
| Q3 2017 | 92 | $3.02B | +$108M | -$267M | -$158M | T, VZ, CVX, RDSB, DWDP | 13F-HR | 11/1/2017, 09:53 AM |
| Q2 2017 | 94 | $3.07B | +$165M | $0 | +$165M | T, VZ, CVX, CAT, PM | 13F-HR | 8/2/2017, 03:36 PM |
| Q1 2017 | 92 | $2.9B | +$98.2M | -$39.6M | +$58.6M | T, VZ, CVX, CAT, IBM | 13F-HR | 5/22/2017, 09:08 AM |
| Q4 2016 | 88 | $2.79B | +$37.9M | -$24.3M | +$13.6M | T, VZ, CVX, CAT, IBM | 13F-HR | 1/31/2017, 10:22 AM |
| Q3 2016 | 90 | $1.65B | $0 | $0 | T, CVX, VZ, BP, IBM | 13F-HR | 11/17/2016, 10:04 AM | |
| Q2 2016 | 87 | $2.24B | +$126M | -$26.3M | +$100M | T, VZ, CVX, GSK, RDSB | 13F-HR | 8/2/2016, 04:39 PM |
| Q1 2016 | 83 | $2.03B | +$253M | -$236M | +$17.5M | T, VZ, GSK, CVX, MCY | 13F-HR | 5/25/2016, 11:11 AM |
| Q4 2015 | 89 | $1.87B | +$74.2M | -$110M | -$35.7M | T, VZ, GSK, CVX, GE | 13F-HR | 2/25/2016, 06:45 PM |
| Q3 2015 | 88 | $1.16B | +$221M | -$79.8M | +$141M | T, VZ, GSK, GE, PG | 13F-HR | 11/4/2015, 12:53 PM |
| Q2 2015 | 86 | $1.74B | +$27.6M | -$28.5M | -$889K | T, VZ, BP, CVX, COP | 13F-HR | 8/5/2015, 05:27 PM |
| Q1 2015 | 84 | $1.79B | +$86.4M | -$33.3M | +$53.1M | T, VZ, CVX, BP, GSK | 13F-HR | 6/18/2015, 10:39 AM |
| Q4 2014 | 87 | $1.75B | +$495M | -$53.8M | +$441M | T, VZ, CVX, COP, BP | 13F-HR | 2/27/2015, 04:52 PM |
| Q3 2014 | 86 | $1.23B | +$126M | -$32.2M | +$93.5M | T, MCD, VZ, MCY, INTC | 13F-HR | 11/7/2014, 08:28 AM |
| Q2 2014 | 87 | $1.15B | +$265M | -$95.8M | +$169M | T, VZ, COP, CVX, INTC | 13F-HR | 8/6/2014, 03:26 PM |
| Q1 2014 | 91 | $940M | +$349M | -$185M | +$164M | T, VZ, MO, KMB, COP | 13F-HR | 5/6/2014, 03:52 PM |
| Q4 2013 | 64 | $763M | $0 | $0 | VRSK, VZ, T, LMT, RTN | Restatement | 2/14/2014, 06:49 PM |